About Beacon Biosignals
Beacon Biosignals is a precision medicine company transforming brain health through AI-driven neurotechnology. The company operates a comprehensive platform that collects, integrates, and analyzes neurophysiological and cardiopulmonary data to accelerate drug development and enable scalable home sleep testing diagnostics. Beacon's technology serves two primary markets: life sciences companies conducting clinical trials and research, and healthcare providers delivering at-home sleep diagnostics. The platform centers on the FDA 510(k)-cleared Waveband EEG headband (formerly Dreem 3S), which collects clinical-grade sleep staging data equivalent to polysomnography in patients' natural environments. Data is securely uploaded to the Beacon Datastore, where advanced AI and machine learning algorithms characterize patient-level and population-level brain function. The company supports pharmaceutical companies throughout Phase 1-4 drug development with comprehensive clinical study operations and scientific services. For healthcare providers, Beacon offers scalable at-home sleep testing solutions including Sleepview Direct and the SleepView Monitor. The company is building the world's largest clinically validated neurophysiology dataset, having analyzed over 2 million hours of EEG data, supported 40+ clinical trials, and completed 500,000+ home sleep tests. Beacon's mission is to transform treatment for patients from clinical development to clinical practice, enabling life-changing therapies to reach the right patients faster through precision neuroscience.
Mission & Story
Mission
Transforming treatment for patients, from clinical development to clinical practice
Clinical Focus
Medical conditions and clinical areas addressed by Beacon Biosignals.
Who It Serves
Milestones & Awards
Recent Milestones
Series B financing upsized to over $97 million (April 2026), Named in Fast Company's Most Innovative Companies of 2026 (March 2026), Partnership with Harmony Biosciences announced (December 2025)
Awards & Recognition
Fast Company's Most Innovative Companies of 2026
Key Partnerships
Company Details
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingSecurity & Compliance
Official Sources
Similar Companies in this Market
View all 60 →
23andMe
23andMe uses AI to analyze genetic data and provide personalized health summaries, risk assessments, and wellness recommendations based on genomic insights.
2bPrecise
AI-powered precision medicine platform for personalized treatment recommendations and genomic analysis.
ACT Genomics
AI-powered genomic analysis platform for precision medicine and personalized treatment recommendations.
Adaptive Biotechnologies
Adaptive Biotechnologies uses AI and machine learning to decode the immune system and identify disease-specific immune signatures for diagnosis and personalized treatment.
Ambry Genetics
Ambry Genetics is a leading clinical genetic testing laboratory specializing in hereditary cancer, rare disease, cardiology, and neurology testing. The company provides advanced genetic testing solutions with paired DNA/RNA analysis and comprehensive patient support programs.
Ataraxis
Ataraxis develops AI-native precision medicine tools that predict patient outcomes and treatment response in oncology. Their flagship product, Ataraxis Breast, provides clinically validated prognostic and predictive tests for breast cancer using multi-modal AI analysis of pathology images and clinical data.
Avenda Health
Avenda Health develops Unfold AI, an FDA-cleared artificial intelligence platform that creates 3D cancer estimation maps for prostate cancer. The technology analyzes standard-of-care data (MRI, biopsy, pathology, PSA) to visualize cancer location and extent, helping physicians make more informed treatment decisions and improve patient outcomes.
Base Genomics
Base Genomics appears to be a company in the Precision Medicine & Genomics space, but the scraped website content is empty or inaccessible, preventing detailed analysis of their offerings and target market.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.